Docket Number:28A-940701B
Inventor:Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
IP Status:US 7,943,134、TW I403586、CN ZL200880129343、PCT pending
Abstract:
According to WHO data, it is estimated that about 2.5 billions of people worldwide live in the highly endemic areas of dengue fever. There are 50 millions of people diagnosed to be dengue fever each year with a mortality rate about 0.05%; in the other world, there are 25 thousands of people died of dengue fever each year. The trend of the average case notification also grows year by year, and the notified cases in 2008 have reached approximately 100 millions of people. Due to global warming in recent years, the epidemic of dengue fever is growing rapidly and not limited anymore in the tropical areas that prompts more and more national attentions to the prevention and treatment of dengue fever. There has no specific drugs for dengue fever treatment, and currently anti-inflammation drugs combined with supportive therapy are clinically applied. The present invention discovered that DVLR1 (CLEC5A) in the presence or absence of calcium ions can directly bind dengue virus and a monoclonal antibody recognizing DVLR1 can block the interaction between DV and DVLR1 that consequently causes the inhibition of massive tumor necrosis factor-α (TNF- α) release. The objective of this invention is to develop a new drug targeting DVLR1 to prevent the serious complications arising from dengue fever, therefore, effectively reduces the death rate caused by dengue hemorrhagic fever and dengue shock syndrome.
Fields of Application:
The monoclonal antibody (mAb) once is successfully developed to become a new drug, it will be the first drug in the world to treat dengue virus infection. It is expected to contribute to other viral diseases associated with receptor-mediated inflammatory responses of Flaviviridae including JEV, West Nile virus (WNV) and yellow fever virus. Additionally, CLEC5A mAb has the potentials for autoimmune diseases, which are regulated by similar immune mechanisms.
Advantages when compared to the existing technologies:
There is no effective way to treat dengue fever currently. Infected patients are treated with drugs to inhibit inflammation, highly recommended for bed rest, rehydrated to prevent an excess loss of body fluids, given antipyretic when a high fever happened, and given painkiller to relieve pain. For critically ill patients, in addition to the aforementioned therapy, also in line with the necessary physical examinations to follow up the patients’ status in order to give the corresponding supportive treatments. Therefore, the therapeutic antibody in the future will significantly improve the treatment of dengue fever, at the reduction of mortality rate as well as the symptom relief, and be more advanced and effective than the current therapy.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
